Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 501 results for cost benefit of cancer drugs

  1. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

  2. Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

    Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

  3. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA1167)

    Evidence-based recommendations on serplulimab (Hetronifly) with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer in adults.

  4. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.

  5. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

  6. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

  7. Kidney cancer: diagnosis and management (NG256)

    This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.

  8. Past research and projects

    NICE's past research and projects

  9. Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.

  10. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

    Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.

  11. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

  12. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

  13. Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)

    Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  14. Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

  15. Heavy menstrual bleeding: assessment and management (NG88)

    This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.